Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan

NCT04818385 ·Status: COMPLETED

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

NCT03219437 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

NCT04102007 ·Status: COMPLETED ·Phase: PHASE3

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

NCT03478787 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT07039110 ·Status: RECRUITING

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00292396 ·Status: COMPLETED ·Phase: PHASE2

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

NCT06333860 ·Status: COMPLETED ·Phase: PHASE4

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

NCT01597245 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512 ·Status: COMPLETED ·Phase: PHASE3

High Dose Risankizumab for Psoriasis

NCT05283135 ·Status: COMPLETED ·Phase: PHASE2

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

NCT03518047 ·Status: COMPLETED ·Phase: PHASE3

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT03000075 ·Status: COMPLETED ·Phase: PHASE2

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03410992 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

NCT04862286 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

NCT02672852 ·Status: COMPLETED ·Phase: PHASE3

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475 ·Status: COMPLETED ·Phase: PHASE4

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02203851 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

NCT04433442 ·Status: COMPLETED

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT05364554 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

NCT03671148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03598790 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

NCT01555606 ·Status: COMPLETED

A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

NCT02387801 ·Status: COMPLETED ·Phase: PHASE3

Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)

NCT05685940 ·Status: RECRUITING ·Phase: PHASE4

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

NCT02719171 ·Status: COMPLETED ·Phase: PHASE2